Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Leukemia

Free Subscription Articles published in Am J Hematol Retrieve available abstracts of 165 articles: HTML format

Single Articles

June 2025
1. STAGNO F, Cucci R, Marsili G, Castagnetti F, et al
   Outcome of Chronic Myeloid Leukemia Patients Not in Deep Molecular Response: Results From the GIMEMA LabNet CML Network Database.
   Am J Hematol. 2025 Jun 5. doi: 10.1002/ajh.27733.
   PubMed    
   
   
   
2. SHAH MV, Arber DA, Hiwase DK
   TP53 -Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk-Stratification, and Management.
   Am J Hematol. 2025;100 Suppl 4.
   PubMed     Abstract available
   
   
   May 2025
3. BAZARBACHI A, Galimard JE, Dalle IA, Socie G, et al
   Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Allografted in First Remission: From EBMT ALWP.
   Am J Hematol. 2025 May 30. doi: 10.1002/ajh.27726.
   PubMed     Abstract available
   
   
   
4. GANGAT N, Tefferi A
   CPX-351 (Vyxeos) in Acute Myeloid Leukemia: Time to Move on?
   Am J Hematol. 2025 May 29. doi: 10.1002/ajh.27730.
   PubMed     Abstract available
   
   
   
5. KADIA TM, Jen WY, Bataller A, Bazinet A, et al
   A Phase 2 Trial of CPX-351 Combined With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia.
   Am J Hematol. 2025 May 22. doi: 10.1002/ajh.27723.
   PubMed     Abstract available
   
   
   
6. KANTARJIAN H, Jabbour E
   Adult Acute Lymphoblastic Leukemia: 2025 Update on Diagnosis, Therapy, and Monitoring.
   Am J Hematol. 2025 May 16. doi: 10.1002/ajh.27708.
   PubMed     Abstract available
   
   
   
7. OKADA Y, Kondo T, Miyazaki T, Shimazu Y, et al
   Optimal Depth of the Treatment Response Before Allogeneic Hematopoietic Transplantation for Chronic Myeloid Leukemia in Chronic Phase.
   Am J Hematol. 2025 May 12. doi: 10.1002/ajh.27706.
   PubMed    
   
   
   
8. CHALANDON Y, Devillier R, Boumendil A, Nguyen S, et al
   Allogeneic Hematopoietic Stem Cell Transplantation for Elderly Acute Lymphoblastic Leukemia Patients: A Registry Study From the Societe Francophone de Greffe de Moelle et Therapie Cellulaire (SFGM-TC).
   Am J Hematol. 2025 May 6. doi: 10.1002/ajh.27701.
   PubMed     Abstract available
   
   
   April 2025
9. OLSON LM, Gurney M, Li M, Yao Y, et al
   Acute Megakaryoblastic Leukemia Masquerading as a Germ Cell Tumor.
   Am J Hematol. 2025 Apr 28. doi: 10.1002/ajh.27698.
   PubMed    
   
   
   
10. KAMASO J, Garcia-Serra R, Munne M, Rodriguez-Rivera M, et al
    Integrating Optical Genome Mapping With TP53 FISH: A Synergistic Approach for Cytogenomic Analysis in Chronic Lymphocytic Leukemia.
    Am J Hematol. 2025 Apr 25. doi: 10.1002/ajh.27690.
    PubMed    
    
    
    
11. YE Y, Berland ATF, Labopin M, Chen J, et al
    Better Outcome Following Younger Haploidentical Donor Versus Older Matched Unrelated Donor Transplant for Fit Patients With Acute Myeloid Leukemia Transplanted in First Remission: A Study From the Global Committee and the Acute Leukemia Working Party
    Am J Hematol. 2025 Apr 7. doi: 10.1002/ajh.27681.
    PubMed    
    
    
    
12. TEFFERI A, Arber DA
    Prognostic Validation of the International Consensus (ICC) Re-Classification of Acute Myeloid Leukemia With Myelodysplasia-Related Changes (AML-MRC) Into Genetic Subcategories.
    Am J Hematol. 2025 Apr 2. doi: 10.1002/ajh.27675.
    PubMed    
    
    
    March 2025
13. BENITEZ LL, Marx KR, Rausch CR, Buhlinger KM, et al
    Multicenter Retrospective Evaluation of Treatment for High-Risk Acute Promyelocytic Leukemia: Real-World Outcomes From the HERO Consortium.
    Am J Hematol. 2025 Mar 26. doi: 10.1002/ajh.27667.
    PubMed     Abstract available
    
    
    
14. PETIT C, Higue J, Acheaibi Z, Gilhodes J, et al
    Venetoclax-Azacitidine Versus Azacitidine for the Treatment of Primary Refractory or First Relapsed Acute Myeloid Leukemia. An IPC-DATAML-MSKCC Retrospective Study.
    Am J Hematol. 2025 Mar 15. doi: 10.1002/ajh.27626.
    PubMed    
    
    
    
15. FATHIMA S, Abdelmagid M, Alsugair A, Begna KH, et al
    Multihit TP53 Mutations in Myeloproliferative Neoplasms and Acute Myeloid Leukemia: Comparative Analysis of Survival and Risk Factors in 142 Informative Cases.
    Am J Hematol. 2025 Mar 13. doi: 10.1002/ajh.27670.
    PubMed     Abstract available
    
    
    
16. CHIEN KS, Curry JL, Pemmaraju N, Jain N, et al
    Leukemia Cutis in the Setting of Indolent Chronic Lymphocytic Leukemia.
    Am J Hematol. 2025 Mar 10. doi: 10.1002/ajh.27654.
    PubMed    
    
    
    
17. ROJEK AE, McCormick BJ, Cwykiel J, Odetola O, et al
    Real-World Outcomes of Relapsed/Refractory Core-Binding Factor Acute Myeloid Leukemia: A COMMAND Registry Study.
    Am J Hematol. 2025 Mar 10. doi: 10.1002/ajh.27664.
    PubMed    
    
    
    
18. ESTEVE J, Nagler A, Labopin M, Versluis J, et al
    Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Genetic Features: Relevance of the Genetic Underlying Category. A Retrospective Analysis on Behalf of the Acute Leukemia Working Party of
    Am J Hematol. 2025 Mar 10. doi: 10.1002/ajh.27647.
    PubMed     Abstract available
    
    
    
19. BRUNO JE, Herne CA, Baran AM, VanDerMeid KR, et al
    Treatment of Relapsed/Refractory CLL Patients With PI3Kdelta Inhibitor and Anti-CD20 Antibody Rapidly Decreases Tumor Burden but Could Induce Resistance.
    Am J Hematol. 2025;100:523-526.
    PubMed     Abstract available
    
    
    
20. MOORE CG, Stein A, Fathi AT, Pullarkat V, et al
    Treatment of Relapsed/Refractory AML-Novel Treatment Options Including Immunotherapy.
    Am J Hematol. 2025;100 Suppl 2:23-37.
    PubMed     Abstract available
    
    
    
21. RAVANDI F
    Therapeutic Advances and Future of Therapy in Acute Myeloid Leukemia.
    Am J Hematol. 2025;100 Suppl 2:3-4.
    PubMed    
    
    
    
22. PRATZ KW, Erba HP
    Frontline Therapy of AML in the Fit and Younger Population-Incorporating Molecularly Targeted Agents.
    Am J Hematol. 2025;100 Suppl 2:16-22.
    PubMed     Abstract available
    
    
    
23. GOULART H, Wei AH, Kadia TM
    Maintenance Therapy in AML: What Is the Future Potential?
    Am J Hematol. 2025;100 Suppl 2:38-49.
    PubMed     Abstract available
    
    
    
24. SHORT NJ, Dillon R
    Measurable residual disease monitoring in AML: Prospects for therapeutic decision-making and new drug development.
    Am J Hematol. 2025;100 Suppl 2:5-15.
    PubMed     Abstract available
    
    
    February 2025
25. QU S, Liu N, Sun Q, Wang H, et al
    The Molecular Features of Chronic Eosinophilic Leukemia, Not Otherwise Specified.
    Am J Hematol. 2025 Feb 25. doi: 10.1002/ajh.27645.
    PubMed    
    
    
    
26. DE LIMA M, Kebriaei P, Lanza F, Cho C, et al
    Five-Year Real-World Safety of Inotuzumab Ozogamicin Before Hematopoietic Stem Cell Transplantation in B-Cell Precursor Acute Lymphoblastic Leukemia.
    Am J Hematol. 2025 Feb 24. doi: 10.1002/ajh.27637.
    PubMed    
    
    
    
27. ROEKER LE, Han Y, Teschemaker A, Mato AR, et al
    BTK Inhibitors Versus Venetoclax as First- or Second-Line Therapy in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Evidence Study.
    Am J Hematol. 2025 Feb 17. doi: 10.1002/ajh.27639.
    PubMed    
    
    
    
28. SU W, Stricherz M, Martin A, Belsey J, et al
    The Efficacy of Pediatric-Inspired Regimens vs. Hyper-CVAD in the Treatment of Adolescents and Young Adults With Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis.
    Am J Hematol. 2025 Feb 13. doi: 10.1002/ajh.27607.
    PubMed     Abstract available
    
    
    
29. SHIMONY S, Stahl M, Stone RM
    Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management.
    Am J Hematol. 2025 Feb 12. doi: 10.1002/ajh.27625.
    PubMed     Abstract available
    
    
    
30. CANALI A, Rieu JB, Lapierre L, Bain BJ, et al
    BCR::ABL1-Positive Acute Myeloid Leukemia.
    Am J Hematol. 2025 Feb 11. doi: 10.1002/ajh.27633.
    PubMed    
    
    
    
31. ITONAGA H, Miyazaki Y, Kondo T, Shimazu Y, et al
    Long-Term Survival After Allogeneic Hematopoietic Stem Cell Transplantation for BCR::ABL1-Negative Atypical Chronic Myeloid Leukemia: A Nationwide Retrospective Study by Adult CML/MPN and MDS Working Groups of the Japanese Society for Transplantation
    Am J Hematol. 2025 Feb 11. doi: 10.1002/ajh.27641.
    PubMed    
    
    
    
32. SENAPATI J, Loghavi S, Marvin-Peek J, Garcia-Manero G, et al
    Clinico-Genomic Interrogation of Secondary-Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary Therapies.
    Am J Hematol. 2025 Feb 8. doi: 10.1002/ajh.27628.
    PubMed     Abstract available
    
    
    
33. 
    Correction to "Secondary-Type Mutations Do Not Impact Prognosis in Acute Myelogenous Leukemia AML With Mutated NPM1".
    Am J Hematol. 2025 Feb 5. doi: 10.1002/ajh.27629.
    PubMed    
    
    
    
34. SHIMONY S, Garcia JS
    Sharpening the Tools to Get the Edge on Leukemia.
    Am J Hematol. 2025 Feb 4. doi: 10.1002/ajh.27622.
    PubMed    
    
    
    
35. CHEN EC, Shimony S, Luskin MR, Stone RM, et al
    Biology and Management of Acute Myeloid Leukemia With Mutated NPM1.
    Am J Hematol. 2025 Feb 4. doi: 10.1002/ajh.27600.
    PubMed     Abstract available
    
    
    January 2025
36. MAYER J, Cicatkova P, Kovacova L, Jarosova M, et al
    Clinical and Prognostic Significance of Additional Chromosomal Abnormalities at Diagnosis of Chronic Myeloid Leukemia.
    Am J Hematol. 2025 Jan 28. doi: 10.1002/ajh.27608.
    PubMed     Abstract available
    
    
    
37. HALLEK M
    Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy.
    Am J Hematol. 2025 Jan 28. doi: 10.1002/ajh.27546.
    PubMed     Abstract available
    
    
    
38. WEI Q, Hu S, Loghavi S, Toruner GA, et al
    Chromoanagenesis Is Frequently Associated With Highly Complex Karyotypes, Extensive Clonal Heterogeneity, and Treatment Refractoriness in Acute Myeloid Leukemia.
    Am J Hematol. 2025 Jan 27. doi: 10.1002/ajh.27575.
    PubMed     Abstract available
    
    
    
39. ENGELMANN R, Flores-Montero J, Schilperoord-Vermeulen J, Ritgen M, et al
    Novel Flow Cytometric Antibody Panel and Dedicated Analysis Algorithm for Automated Fully Standardized Minimal Residual Disease Detection in Chronic Lymphocytic Leukemia.
    Am J Hematol. 2025 Jan 25. doi: 10.1002/ajh.27604.
    PubMed    
    
    
    
40. BUTLER JT, Yashar WM, Swords R
    Breaking the Bone Marrow Barrier: Peripheral Blood as a Gateway to Measurable Residual Disease Detection in Acute Myelogenous Leukemia.
    Am J Hematol. 2025 Jan 7. doi: 10.1002/ajh.27586.
    PubMed     Abstract available
    
    
    
41. KANTARJIAN H, Short NJ, Jain N, Haddad FG, et al
    Hyper-CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia.
    Am J Hematol. 2025 Jan 5. doi: 10.1002/ajh.27576.
    PubMed     Abstract available
    
    
    
42. LUFT T, Gras L, Koster L, Kroger N, et al
    Methotrexate Versus Mycophenolate Mofetil Prophylaxis in Allogeneic Hematopoietic Cell Transplantation for Chronic Myeloid Malignancies: A Retrospective Analysis on Behalf of the Chronic Malignancies Working Party of the EBMT.
    Am J Hematol. 2025;100:38-51.
    PubMed     Abstract available
    
    
    
43. RECHER C, Dumas PY, Berard E, Tavitian S, et al
    Mini-consolidations or intermediate-dose cytarabine for the post-remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries.
    Am J Hematol. 2025;100:23-32.
    PubMed     Abstract available
    
    
    December 2024
44. SENAPATI J, Kantarjian HM, Haddad FG, Short NJ, et al
    Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High-Risk Subtype That Warrants an Independent Prognostic Designation.
    Am J Hematol. 2024 Dec 24. doi: 10.1002/ajh.27561.
    PubMed     Abstract available
    
    
    
45. GHOSH N, Eyre TA, Brown JR, Lamanna N, et al
    Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study.
    Am J Hematol. 2024 Dec 19. doi: 10.1002/ajh.27563.
    PubMed    
    
    
    
46. GANGAT N, Elbeih A, Ghosoun N, McCullough K, et al
    Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent.
    Am J Hematol. 2024 Dec 13. doi: 10.1002/ajh.27564.
    PubMed     Abstract available
    
    
    
47. CAIROLI R, Gatti A, Grillo G, Stefanucci MR, et al
    Efficacy of Midostaurin Combined With Intensive Chemotherapy in Core Binding Factor Leukemia: A Phase II Clinical Trial.
    Am J Hematol. 2024 Dec 10. doi: 10.1002/ajh.27547.
    PubMed     Abstract available
    
    
    
48. GUERINEAU H, Cayuela JM, Dulucq S, Tran Quang V, et al
    Mutation of Epigenetic Regulators at Diagnosis Is an Independent Predictor of Tyrosine Kinase Inhibitor Treatment Failure in Chronic Myeloid Leukemia: A Report From the RESIDIAG Study.
    Am J Hematol. 2024 Dec 10. doi: 10.1002/ajh.27553.
    PubMed    
    
    
    
49. STUTE N, Koldehoff M
    Overall Survival in Male Patients With Advanced Hematological Disease (Mostly Acute Leukemia) Is Influenced by CYP1B1 C432G Polymorphism and Donor Sex in Allogeneic Stem Cell Transplantation.
    Am J Hematol. 2024 Dec 3. doi: 10.1002/ajh.27538.
    PubMed    
    
    
    November 2024
50. KIRTEK TJ, Chen W, Harris JC, Bagg A, et al
    Acute Leukemias of Ambiguous Lineage With MDS-Associated Mutations Show Similar Prognosis Compared to Acute Myeloid Leukemia With MDS-Associated Mutations: A Study From the Bone Marrow Pathology Group.
    Am J Hematol. 2024 Nov 23. doi: 10.1002/ajh.27537.
    PubMed    
    
    
    
51. ROY MOULIK N, Keerthivasagam S, Chatterjee G, Agiwale J, et al
    Treatment-Free Remissions in Children With Chronic Myeloid Leukemia (CML): A Prospective Study From the Tata Memorial Hospital (TMH) Pediatric CML (pCML) Cohort.
    Am J Hematol. 2024 Nov 20. doi: 10.1002/ajh.27528.
    PubMed     Abstract available
    
    
    
52. KONUMA T, Kameda K, Morita K, Kondo T, et al
    Different impacts of granulocyte colony-stimulating factor administration on allogeneic hematopoietic cell transplant outcomes for adult acute myeloid leukemia according to graft type.
    Am J Hematol. 2024 Nov 20. doi: 10.1002/ajh.27521.
    PubMed     Abstract available
    
    
    
53. SCHMALTER AK, Labopin M, Versluis J, Gallego Hernanz MP, et al
    The role of allogeneic stem cell transplantation in acute myeloid leukemia with translocation t(8;16)(p11;p13).
    Am J Hematol. 2024 Nov 18. doi: 10.1002/ajh.27496.
    PubMed     Abstract available
    
    
    
54. LIU H, Xu H, Chi P, Feng Z, et al
    A prophylactic tyrosine kinase inhibitor strategy based on measurable residual disease pre-transplantation for Ph(+) acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation: A prospective multicenter cohort study.
    Am J Hematol. 2024 Nov 16. doi: 10.1002/ajh.27516.
    PubMed     Abstract available
    
    
    
55. LUO J, Zhang J, Liu L, Wei R, et al
    Efficacy and safety of zanubrutinib monotherapy for chronic lymphocytic leukemia/small lymphocytic lymphoma: A multicenter, real-world study in China.
    Am J Hematol. 2024 Nov 4. doi: 10.1002/ajh.27519.
    PubMed    
    
    
    
56. HEIBLIG M, Gourguechon C, Guilpain P, Bulai-Livideanu C, et al
    Comparison of prognostic scores according to WHO classification in 170 patients with advanced mastocytosis and C-finding treated with midostaurin.
    Am J Hematol. 2024;99:2127-2139.
    PubMed     Abstract available
    
    
    
57. DINARDO CD, Pratz KW, Panayiotidis P, Wei X, et al
    The impact of post-remission granulocyte colony-stimulating factor use in the phase 3 studies of venetoclax combination treatments in patients with newly diagnosed acute myeloid leukemia.
    Am J Hematol. 2024 Nov 1. doi: 10.1002/ajh.27515.
    PubMed    
    
    
    October 2024
58. SHANKER S, Hasserjian RP, Madanat Y, Weinberg OK, et al
    Impact of myelodysplasia-related mutations on 2022 European LeukemiaNet genetic risk classification in de novo acute myeloid leukemia with normal karyotype.
    Am J Hematol. 2024 Oct 30. doi: 10.1002/ajh.27518.
    PubMed     Abstract available
    
    
    
59. ONIDA F
    Harnessing the prognostic potential of PHF6 mutations in chronic myelomonocytic leukemia.
    Am J Hematol. 2024 Oct 29. doi: 10.1002/ajh.27512.
    PubMed    
    
    
    
60. 
    Abstracts from the 2024 Lymphoma Leukemia and Myeloma Congress October 16-19, 2024.
    Am J Hematol. 2024;99 Suppl 2:S3-S64.
    PubMed    
    
    
    September 2024
61. SRINIVASAN N, Olivier T, Haslam A, Prasad V, et al
    Imatinib remains the best frontline therapy in patients with chronic myeloid leukemia: Critical analysis of the ASC4FIRST trial.
    Am J Hematol. 2024 Sep 28. doi: 10.1002/ajh.27477.
    PubMed    
    
    
    
62. TEFFERI A, Fathima S, Alsugair AKA, Aperna F, et al
    PHF6 mutations in chronic myelomonocytic leukemia identify a unique subset of patients with distinct phenotype and superior prognosis.
    Am J Hematol. 2024 Sep 27. doi: 10.1002/ajh.27492.
    PubMed     Abstract available
    
    
    
63. OZGA M, Nicolet D, Mrozek K, Walker CJ, et al
    White blood cell count levels are associated with inflammatory response and constitute independent outcome predictors in adult patients with acute myeloid leukemia aged <60 years.
    Am J Hematol. 2024 Sep 16. doi: 10.1002/ajh.27465.
    PubMed    
    
    
    
64. BADAR T, Narra R, Mims AS, Heckman MG, et al
    Impact of induction regimens intensity and allogeneic stem cell transplantation on survival of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A multi-institutional study.
    Am J Hematol. 2024 Sep 10. doi: 10.1002/ajh.27475.
    PubMed     Abstract available
    
    
    
65. BAUER K, Hauswirth A, Gleixner KV, Greiner G, et al
    BRD4 degraders may effectively counteract therapeutic resistance of leukemic stem cells in AML and ALL.
    Am J Hematol. 2024;99:1721-1731.
    PubMed     Abstract available
    
    
    August 2024
66. BARON F, Labopin M, Versluis J, Vydra J, et al
    Higher survival following transplantation with a mismatched unrelated donor with posttransplant cyclophosphamide-based graft-versus-host disease prophylaxis than with double unit umbilical cord blood in patients with acute myeloid leukemia in first co
    Am J Hematol. 2024 Aug 31. doi: 10.1002/ajh.27466.
    PubMed     Abstract available
    
    
    
67. ZIMMERMAN MKA, Wilde L
    Oh node: Extranodal nodular involvement of chronic lymphocytic leukemia in the colon.
    Am J Hematol. 2024 Aug 28. doi: 10.1002/ajh.27467.
    PubMed    
    
    
    
68. JEN WY, Jabbour E, Short NJ, Issa GC, et al
    A phase 2 trial of mini-hyper-CVD, blinatumomab, and ponatinib in Philadelphia positive acute lymphoblastic leukemia.
    Am J Hematol. 2024 Aug 28. doi: 10.1002/ajh.27463.
    PubMed     Abstract available
    
    
    
69. HAZARIKA B, Bain BJ
    Presentation of chronic myeloid leukemia in basophilic blast crisis.
    Am J Hematol. 2024 Aug 23. doi: 10.1002/ajh.27464.
    PubMed    
    
    
    
70. SHEN Q, Jabbour EJ, Tang G, Fang H, et al
    Secondary acquisition of the Philadelphia chromosome in acute lymphoblastic leukemia.
    Am J Hematol. 2024 Aug 17. doi: 10.1002/ajh.27462.
    PubMed    
    
    
    
71. LIPTON JH
    Imatinib versus newer generation TKIs for upfront therapy in chronic phase chronic myeloid leukemia: What is the rationale for paying more to get the same survival benefit?
    Am J Hematol. 2024 Aug 14. doi: 10.1002/ajh.27455.
    PubMed    
    
    
    
72. JABBOUR E, Kantarjian H
    Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring.
    Am J Hematol. 2024 Aug 2. doi: 10.1002/ajh.27443.
    PubMed     Abstract available
    
    
    
73. KANTARJIAN HM, Begna K, Jabbour EJ, Paul S, et al
    Optimal frontline therapy of chronic myeloid leukemia today, and related musings.
    Am J Hematol. 2024 Aug 2. doi: 10.1002/ajh.27445.
    PubMed    
    
    
    
74. SMITH CJ, Ruan GJ, Kluck LA, Maberry M, et al
    BCR-ABL testing in the evaluation of neutrophilia.
    Am J Hematol. 2024;99:1651-1654.
    PubMed    
    
    
    
75. KANTARJIAN HM, Chifotides HT, Haddad FG, Short NJ, et al
    Ponatinib-review of historical development, current status, and future research.
    Am J Hematol. 2024;99:1576-1585.
    PubMed     Abstract available
    
    
    July 2024
76. WILLEMSEN M, Smeets P, de Coninck A
    Isolated peripheral nervous system relapse after allogeneic hematopoietic cell transplantation for T-cell acute lymphoblastic leukemia.
    Am J Hematol. 2024 Jul 30. doi: 10.1002/ajh.27441.
    PubMed    
    
    
    
77. MOLICA S, Allsup D, Giannarelli D
    Network meta-analysis of upfront fixed-duration therapies in chronic lymphocytic leukemia.
    Am J Hematol. 2024 Jul 23. doi: 10.1002/ajh.27437.
    PubMed    
    
    
    
78. LOGHAVI S, Wei Q, Ravandi F, Quesada AE, et al
    Optical genome mapping improves the accuracy of classification, risk stratification, and personalized treatment strategies for patients with acute myeloid leukemia.
    Am J Hematol. 2024 Jul 17. doi: 10.1002/ajh.27435.
    PubMed     Abstract available
    
    
    
79. MARVIN-PEEK J, Gilbert JS, Pollyea DA, DiNardo CD, et al
    Frontline therapy of acute myeloid leukemia with lower intensity regimens: Where are we now and where can we go?
    Am J Hematol. 2024 Jul 17. doi: 10.1002/ajh.27434.
    PubMed     Abstract available
    
    
    
80. BALEV M, Zibara V, Van Hyfte G, Feld J, et al
    Evaluating the role of Day 14 bone marrow biopsy and European LeukemiaNet risk classification in predicting overall and relapse-free survival in acute myeloid leukemia.
    Am J Hematol. 2024 Jul 5. doi: 10.1002/ajh.27429.
    PubMed     Abstract available
    
    
    
81. TU S, Zhou L, Huang R, Zhou X, et al
    Dendritic cell vaccines extend CAR T-cell persistence and improve the efficacy of CD19 CAR T-cell therapy in refractory or relapsed adult B-ALL patients.
    Am J Hematol. 2024;99:1437-1440.
    PubMed    
    
    
    
82. PEREZ CARRETERO C, Gonzalez T, Quijada Alamo M, Rigolin GM, et al
    Chronic lymphocytic leukemia patients with chromosome 6q deletion as the sole cytogenetic abnormality display a high frequency of RPS15 mutations and have a poor prognosis.
    Am J Hematol. 2024 Jul 1. doi: 10.1002/ajh.27421.
    PubMed    
    
    
    June 2024
83. LANCE A, Chiad Z, Seegers SL, Paschall SC, et al
    Hereditary chronic neutrophilic leukemia in a four-generation family without transformation to acute leukemia.
    Am J Hematol. 2024 Jun 27. doi: 10.1002/ajh.27420.
    PubMed     Abstract available
    
    
    
84. VENANZI A, Cardinali V, Perriello V, Albano F, et al
    Starry sky pattern predicts RAS pathway activation in NPM1-mutated acute myeloid leukemia.
    Am J Hematol. 2024 Jun 22. doi: 10.1002/ajh.27415.
    PubMed    
    
    
    
85. GARCIAZ S, Dumas PY, Bertoli S, Sallman DA, et al
    Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment.
    Am J Hematol. 2024 Jun 20. doi: 10.1002/ajh.27417.
    PubMed     Abstract available
    
    
    
86. NAGLER A, Ngoya M, Galimard JE, Labopin M, et al
    Comparable relapse incidence after unrelated allogeneic stem cell transplantation with post-transplant cyclophosphamide versus conventional anti-graft versus host disease prophylaxis in patients with acute myeloid leukemia: A study on behalf of the Ac
    Am J Hematol. 2024 Jun 10. doi: 10.1002/ajh.27383.
    PubMed     Abstract available
    
    
    
87. CLAUDIANI S, Chee L, Fernando F, Brown L, et al
    Treatment-free remission in CML patients with additional chromosome abnormalities in the Philadelphia-positive clone or variant Philadelphia translocations.
    Am J Hematol. 2024;99:1172-1174.
    PubMed     Abstract available
    
    
    May 2024
88. VERONESE L, Bensaber H, Dannus LT, Giannone G, et al
    Molecular landscape of mature B-cell lymphoproliferative disorders with BCL3-translocation: A Groupe Francophone de Cytogenetique Hematologique (GFCH)/French Innovative Leukemia Organization (FILO) study.
    Am J Hematol. 2024 May 30. doi: 10.1002/ajh.27384.
    PubMed    
    
    
    
89. OTHMAN T, Koller P, Tsai NC, Yang D, et al
    Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Am J Hematol. 2024 May 28. doi: 10.1002/ajh.27378.
    PubMed     Abstract available
    
    
    
90. OTHMAN T, Li S, Zhang J, Pourhassan H, et al
    Outcomes following allogeneic hematopoietic cell transplantation relapse in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Am J Hematol. 2024 May 27. doi: 10.1002/ajh.27365.
    PubMed     Abstract available
    
    
    
91. DEVILLIER R, Galimard JE, Blaise D, Raiola AM, et al
    Peripheral blood stem cell versus bone marrow graft for patients >/=60 years undergoing reduced intensity conditioning haploidentical transplantation for acute myeloid leukemia in complete remission: An analysis of the Acute Leukemia Working Party of
    Am J Hematol. 2024 May 23. doi: 10.1002/ajh.27343.
    PubMed     Abstract available
    
    
    
92. KOCKEROLS C, Valk PJM, Dulucq S, Nicolini FE, et al
    BCR::ABL1 digital PCR for treatment-free remission prediction in chronic myeloid leukemia patients: An individual participant data meta-analysis.
    Am J Hematol. 2024 May 20. doi: 10.1002/ajh.27359.
    PubMed    
    
    
    
93. LANGERBEINS P, Giza A, Robrecht S, Cramer P, et al
    Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations.
    Am J Hematol. 2024 May 17. doi: 10.1002/ajh.27367.
    PubMed    
    
    
    
94. BEWERSDORF JP, Shimony S, Shallis RM, Liu Y, et al
    Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort study.
    Am J Hematol. 2024 May 15. doi: 10.1002/ajh.27366.
    PubMed    
    
    
    
95. RANAWEERA ARACHCHIGE T, Mendiburu C, Martin A, Fleury C, et al
    Clinical and biological characterization of involvement of nasal-associated lymphoid tissues in chronic lymphocytic leukemia.
    Am J Hematol. 2024 May 10. doi: 10.1002/ajh.27357.
    PubMed    
    
    
    
96. SHOMALI W, Gotlib J
    World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.
    Am J Hematol. 2024;99:946-968.
    PubMed     Abstract available
    
    
    
97. CIUREA SO, Kongtim P, Srour S, Chen J, et al
    Results of a phase I trial with Haploidentical mbIL-21 ex vivo expanded NK cells for patients with multiply relapsed and refractory AML.
    Am J Hematol. 2024;99:890-899.
    PubMed     Abstract available
    
    
    
98. ORVAIN C, Ali N, Othus M, Rodriguez-Arboli E, et al
    Relative prognostic value of flow cytometric measurable residual disease before allogeneic hematopoietic cell transplantation for adults with MDS/AML or AML.
    Am J Hematol. 2024;99:862-870.
    PubMed     Abstract available
    
    
    
99. NISHIWAKI S, Sugiura I, Fujisawa S, Hatta Y, et al
    Utility of allogeneic stem cell transplantation for adult Ph+ALL with complete molecular remission.
    Am J Hematol. 2024;99:806-815.
    PubMed     Abstract available
    
    
    April 2024
100. YE Y, Labopin M, Gerard S, Yakoub-Agha I, et al
     Lower relapse incidence with haploidentical versus matched sibling or unrelated donor hematopoietic cell transplantation for core-binding factor AML patients in CR2: A study from the Global Committee and the Acute Leukemia Working Party of the Europea
     Am J Hematol. 2024 Apr 24. doi: 10.1002/ajh.27342.
     PubMed     Abstract available
     
     
     
101. ZHOU Z, Zhuo N, Zhou Y, Sun C, et al
     Identification of the characteristics and prognostic impact of FUS::ERG and RUNX1::CBFA2T3 fusion genes in adult acute myeloid leukemia patients.
     Am J Hematol. 2024 Apr 23. doi: 10.1002/ajh.27340.
     PubMed    
     
     
     
102. SZUBER N, Orazi A, Tefferi A
     Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management.
     Am J Hematol. 2024 Apr 21. doi: 10.1002/ajh.27321.
     PubMed     Abstract available
     
     
     
103. SHORT NJ, Jabbour E, Nasr LF, Jain N, et al
     Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing therapy.
     Am J Hematol. 2024 Apr 12. doi: 10.1002/ajh.27329.
     PubMed    
     
     
     
104. CRAMER P, von Tresckow J, Fink AM, Robrecht S, et al
     Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial.
     Am J Hematol. 2024 Apr 5. doi: 10.1002/ajh.27304.
     PubMed    
     
     
     
105. MUSICK JO, Williams EK, Fibben KS, Zhang DY, et al
     Redefining hyperviscosity in acute leukemia: Potential implications for red cell transfusions in the microvasculature.
     Am J Hematol. 2024 Apr 4. doi: 10.1002/ajh.27308.
     PubMed     Abstract available
     
     
     
106. KHAN AA, James D, Andresen V, Atkey J, et al
     Pre-B acute lymphoblastic leukemia presenting with NPM1 and FLT3 mutations.
     Am J Hematol. 2024 Apr 3. doi: 10.1002/ajh.27301.
     PubMed    
     
     
     
107. LITZOW MR
     Building a better blinatumomab.
     Am J Hematol. 2024;99:512-514.
     PubMed    
     
     
     
108. HU S, Jabbour EJ, Hu CY, Tang G, et al
     Recurrent lymphoid and myeloid relapses due to treatment cessations reveal natural history of Ph-positive B-ALL and pose a diagnostic challenge.
     Am J Hematol. 2024;99:721-726.
     PubMed    
     
     
     March 2024
109. HADDAD FG, Sasaki K, Issa GC, Jabbour E, et al
     The presence of additional cytogenetic abnormalities (ACAs) or Philadelphia chromosome variants do not adversely affect the achievement of treatment-free remission in chronic myeloid leukemia.
     Am J Hematol. 2024 Mar 28. doi: 10.1002/ajh.27307.
     PubMed    
     
     
     
110. TANG H, Jia W, Jia S, Dong R, et al
     A new chemotherapy-free regimen of olverembatinib in combination with venetoclax and dexamethasone for newly diagnosed Ph+ acute lymphoblastic leukemia: Preliminary outcomes of a prospective study.
     Am J Hematol. 2024 Mar 14. doi: 10.1002/ajh.27289.
     PubMed    
     
     
     
111. PATNAIK MM, Tefferi A
     Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management.
     Am J Hematol. 2024 Mar 7. doi: 10.1002/ajh.27271.
     PubMed     Abstract available
     
     
     
112. TROUSSARD X, Maitre E, Paillassa J
     Hairy cell leukemia 2024: Update on diagnosis, risk-stratification, and treatment-Annual updates in hematological malignancies.
     Am J Hematol. 2024 Mar 5. doi: 10.1002/ajh.27240.
     PubMed     Abstract available
     
     
     February 2024
113. MIRVIS E, Sairam S, Vainieri E, Tona F, et al
     Pituitary apoplexy in acute promyelocytic leukemia.
     Am J Hematol. 2024 Feb 29. doi: 10.1002/ajh.27277.
     PubMed    
     
     
     
114. JIANG M, Wang X, Yu M, Jiang S, et al
     Report of IRF2BP1 as a novel partner of RARA in variant acute promyelocytic leukemia.
     Am J Hematol. 2024 Feb 27. doi: 10.1002/ajh.27272.
     PubMed     Abstract available
     
     
     
115. SANDBERG Y, Budel LM, Bain BJ
     Neutrophilic leukemoid reaction or chronic neutrophilic leukemia-not always so simple.
     Am J Hematol. 2024 Feb 23. doi: 10.1002/ajh.27268.
     PubMed    
     
     
     
116. GANGAT N, Tefferi A
     Venetoclax in the treatment of acute myeloid leukemia: Beyond VIALE-A.
     Am J Hematol. 2024 Feb 20. doi: 10.1002/ajh.27256.
     PubMed     Abstract available
     
     
     
117. BATALLER A, DiNardo CD, Bazinet A, Daver NG, et al
     Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups.
     Am J Hematol. 2024 Feb 15. doi: 10.1002/ajh.27236.
     PubMed     Abstract available
     
     
     
118. KITTAI AS, Hang Y, Bhat SA, Clark A, et al
     Racial disparities in chronic lymphocytic leukemia/small lymphocytic lymphoma accounting for small molecule inhibitors: A real-world cohort analysis.
     Am J Hematol. 2024 Feb 15. doi: 10.1002/ajh.27241.
     PubMed     Abstract available
     
     
     
119. PRATZ KW, Jonas BA, Pullarkat V, Thirman MJ, et al
     Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia.
     Am J Hematol. 2024 Feb 11. doi: 10.1002/ajh.27246.
     PubMed     Abstract available
     
     
     
120. AUTORE F, Visentin A, Deodato M, Vitale C, et al
     Venetoclax infectious risk score to identify patients with chronic lymphocytic leukemia at high infectious risk during venetoclax treatment: A multicenter SEIFEM study.
     Am J Hematol. 2024 Feb 11. doi: 10.1002/ajh.27247.
     PubMed    
     
     
     
121. ABAZA Y, Winer ES, Murthy GSG, Shallis RM, et al
     Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers.
     Am J Hematol. 2024 Feb 11. doi: 10.1002/ajh.27231.
     PubMed     Abstract available
     
     
     
122. CHEN X, Yuan L, Zhang Y, Wang F, et al
     Advances towards genome-based acute myeloid leukemia classification: A comparative analysis of WHO-HAEM4R, WHO-HAEM5, and International Consensus Classification.
     Am J Hematol. 2024 Feb 6. doi: 10.1002/ajh.27249.
     PubMed     Abstract available
     
     
     
123. JABBOUR E, Zugmaier G, Agrawal V, Martinez-Sanchez P, et al
     Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia.
     Am J Hematol. 2024 Feb 5. doi: 10.1002/ajh.27227.
     PubMed     Abstract available
     
     
     
124. HORNAK T, Mayer J, Cicatkova P, Semerad L, et al
     De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors.
     Am J Hematol. 2024 Feb 5. doi: 10.1002/ajh.27229.
     PubMed     Abstract available
     
     
     
125. BENESOVA A, De Santis S, Polivkova V, Pecherkova P, et al
     Unstable major molecular response as a trigger for next generation sequencing-based BCR::ABL1 mutation testing in chronic myeloid leukemia.
     Am J Hematol. 2024 Feb 5. doi: 10.1002/ajh.27232.
     PubMed    
     
     
     
126. KURITA N, Imahashi N, Chiba S, Tanaka M, et al
     Comparison of fludarabine-based conditioning regimens in adult cord blood transplantation for myeloid malignancy: A retrospective, registry-based study.
     Am J Hematol. 2024;99:236-244.
     PubMed     Abstract available
     
     
     
127. GURNARI C, Pascale MR, Vitale A, Diral E, et al
     Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort.
     Am J Hematol. 2024;99:254-262.
     PubMed     Abstract available
     
     
     
128. DINARDO CD
     Toward an improved understanding of hypomethylating agent and venetoclax therapies.
     Am J Hematol. 2024;99:152-154.
     PubMed    
     
     
     
129. BRUNNER AM, Esteve J, Porkka K, Knapper S, et al
     Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes.
     Am J Hematol. 2024;99:E32-E36.
     PubMed     Abstract available
     
     
     January 2024
130. CAMPANELLA A, Capasso A, Heltai S, Taccetti C, et al
     Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL.
     Am J Hematol. 2024 Jan 24. doi: 10.1002/ajh.27218.
     PubMed     Abstract available
     
     
     
131. IM A, Quann K, Agha M, Raptis A, et al
     Phase 2 study of epigenetic priming with decitabine followed by cytarabine for acute myeloid leukemia in older patients.
     Am J Hematol. 2024 Jan 22. doi: 10.1002/ajh.27212.
     PubMed     Abstract available
     
     
     
132. VARDELL VA, Ermann DA, Fitzgerald L, Shah H, et al
     T-cell prolymphocytic leukemia: Epidemiology and survival trends in the era of novel treatments.
     Am J Hematol. 2024 Jan 19. doi: 10.1002/ajh.27205.
     PubMed     Abstract available
     
     
     
133. 
     Correction to "Analysis of 60 Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia and T-cell Lymphoblastic Lymphoma Treated with CD7-targeted Chimeric Antigen Receptor-T Cell Therapy".
     Am J Hematol. 2024 Jan 15. doi: 10.1002/ajh.27217.
     PubMed    
     
     
     
134. BARON F, Efficace F, Cannella L, Stevens-Kroef M, et al
     Similar efficacy outcomes with peripheral blood stem cell versus bone marrow for autologous stem cell transplantation in acute myeloid leukemia: Long-term follow-up of the EORTC-GIMEMA randomized AML-10 trial.
     Am J Hematol. 2024 Jan 4. doi: 10.1002/ajh.27196.
     PubMed     Abstract available
     
     
     
135. MOUKALLED N, Labopin M, Versluis J, Socie G, et al
     Complex karyotype but not other cytogenetic abnormalities is associated with worse posttransplant survival of patients with nucleophosmin 1-mutated acute myeloid leukemia: A study from the European Society for Blood and Marrow Transplantation Acute Le
     Am J Hematol. 2024 Jan 2. doi: 10.1002/ajh.27187.
     PubMed     Abstract available
     
     
     
136. PELLAND-MARCOTTE MC, Kulkarni K, Tran TH, Stammers D, et al
     Risk factors and clinical impact of thrombosis during induction chemotherapy for pediatric acute lymphoblastic leukemia: A report from CYP-C.
     Am J Hematol. 2024 Jan 2. doi: 10.1002/ajh.27171.
     PubMed     Abstract available
     
     
     
137. SPONSEILER I, Bandian AM, Pusic P, Lion T, et al
     Combinatorial treatment options for highly resistant compound mutations in the kinase domain of the BCR::ABL1 fusion gene in Ph-positive leukemias.
     Am J Hematol. 2024;99:E9-E11.
     PubMed    
     
     
     
138. TEFFERI A, Abdelmagid M, Al-Kali A, Patnaik M, et al
     Granularity in disease classification impacts survival prediction in advanced systemic mastocytosis: A single institution study of 329 informative cases.
     Am J Hematol. 2024;99:21-27.
     PubMed     Abstract available
     
     
     December 2023
139. MOLICA S, Shanafelt TD, Allsup D, Giannarelli D, et al
     Impact of targeted agents on survival of chronic lymphocytic leukemia patients age >65 relative to age- and sex-matched population.
     Am J Hematol. 2023 Dec 15. doi: 10.1002/ajh.27182.
     PubMed     Abstract available
     
     
     
140. KARRAR O, Abdelmagid M, Rana M, Iftikhar M, et al
     Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival.
     Am J Hematol. 2023 Dec 15. doi: 10.1002/ajh.27180.
     PubMed     Abstract available
     
     
     
141. GANGAT N, Karrar O, Iftikhar M, McCullough K, et al
     Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients.
     Am J Hematol. 2023 Dec 10. doi: 10.1002/ajh.27138.
     PubMed     Abstract available
     
     
     
142. JOSHI SK, Pittsenbarger J, Kennedy VE, Peretz CAC, et al
     The FLT3(N701K) mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib.
     Am J Hematol. 2023;98:E364-E368.
     PubMed    
     
     
     
143. OLIVA-ARIZA G, Fuentes-Herrero B, Lecrevisse Q, Carbonell C, et al
     Immune cell kinetics and antibody response in COVID-19 patients with low-count monoclonal B-cell lymphocytosis.
     Am J Hematol. 2023;98:1909-1922.
     PubMed     Abstract available
     
     
     November 2023
144. VALENT P
     Clinical impact of cytomorphology in mast cell leukemia.
     Am J Hematol. 2023 Nov 6. doi: 10.1002/ajh.27146.
     PubMed    
     
     
     
145. BATALLER A, Loghavi S, Gerstein Y, Bazinet A, et al
     Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants.
     Am J Hematol. 2023;98:1780-1790.
     PubMed     Abstract available
     
     
     October 2023
146. GHERGUS D, Martin M, Knapp AM, Delmotte F, et al
     Normal B cells express ZAP70 in chronic lymphocytic leukemia: A link between autoimmunity and lymphoproliferation?
     Am J Hematol. 2023 Oct 19. doi: 10.1002/ajh.27137.
     PubMed     Abstract available
     
     
     
147. SALIBA RM, Kanakry CG, Gadalla S, Kebriaei P, et al
     Effect of donor age in patients with acute myeloid leukemia undergoing haploidentical hematopoietic cell transplantation vary by conditioning intensity and recipient age.
     Am J Hematol. 2023 Oct 18. doi: 10.1002/ajh.27126.
     PubMed     Abstract available
     
     
     
148. KITTAI AS, Skarbnik A, Miranda M, Yong ASM, et al
     A matching-adjusted indirect comparison of acalabrutinib versus zanubrutinib in relapsed or refractory chronic lymphocytic leukemia.
     Am J Hematol. 2023 Oct 9. doi: 10.1002/ajh.27110.
     PubMed    
     
     
     
149. ZHANG L, Yang X, Ge X, Li B, et al
     CMSS1::FLT1 rearrangement leads to ligand-independent activation of FLT1 signaling in acute myeloid leukemia.
     Am J Hematol. 2023 Oct 4. doi: 10.1002/ajh.27108.
     PubMed    
     
     
     
150. SUNG MT, Chen LH, Chiang YW, Jhuang JY, et al
     Deciphering clonal architecture and evolutionary dynamics of secondary acute myeloid leukemia and donor-derived myelodysplastic syndrome using single-cell multi-omics analysis.
     Am J Hematol. 2023 Oct 4. doi: 10.1002/ajh.27121.
     PubMed    
     
     
     
151. HAZARIKA B, Bain BJ
     Pseudo-Chediak-Higashi anomaly in acute myeloid leukemia.
     Am J Hematol. 2023 Oct 4. doi: 10.1002/ajh.27114.
     PubMed    
     
     
     
152. HIRABAYASHI S, Kondo T, Nishiwaki S, Mizuta S, et al
     Impact of MRD on clinical outcomes of unrelated hematopoietic stem cell transplantation in patients with Ph(+) ALL: A retrospective nationwide study.
     Am J Hematol. 2023;98:1606-1618.
     PubMed     Abstract available
     
     
     
153. CALABRESI L, Carretta C, Romagnoli S, Rotunno G, et al
     Clonal dynamics and copy number variants by single-cell analysis in leukemic evolution of myeloproliferative neoplasms.
     Am J Hematol. 2023;98:1520-1531.
     PubMed     Abstract available
     
     
     
154. 
     Abstracts from the 2023 Lymphoma, Leukemia and Myeloma Congress October 18-21, 2023.
     Am J Hematol. 2023;98 Suppl 5:S3-S57.
     PubMed    
     
     
     September 2023
155. VISENTIN A, Chatzikonstantinou T, Scarfo L, Kapetanakis A, et al
     The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL.
     Am J Hematol. 2023 Sep 29. doi: 10.1002/ajh.27093.
     PubMed     Abstract available
     
     
     
156. HADDAD FG, Short NJ
     Treatment discontinuation in chronic myeloid leukemia: When, how, and why?
     Am J Hematol. 2023 Sep 27. doi: 10.1002/ajh.27100.
     PubMed    
     
     
     
157. ZHANG X, Yang J, Li J, Qiu L, et al
     Analysis of 60 patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma treated with CD7-targeted chimeric antigen receptor-T cell therapy.
     Am J Hematol. 2023 Sep 23. doi: 10.1002/ajh.27094.
     PubMed     Abstract available
     
     
     
158. TEFFERI A, Pardanani A, Al-Kali A, Alkhateeb H, et al
     Mast cell cytomorphology and treatment outcome in mast cell leukemia.
     Am J Hematol. 2023 Sep 21. doi: 10.1002/ajh.27105.
     PubMed    
     
     
     
159. ANIL J, Alnemri A, Lytle A, Lockhart B, et al
     Bone marrow fibrosis is associated with non-response to CD19 CAR T-cell therapy in B-acute lymphoblastic leukemia.
     Am J Hematol. 2023 Sep 18. doi: 10.1002/ajh.27098.
     PubMed     Abstract available
     
     
     
160. VON ASMUTH EGJ, Lankester AC, Putter H
     Chronic GvHD in a prognostic model: Graft versus leukemia predictor or immortal time bias?
     Am J Hematol. 2023 Sep 15. doi: 10.1002/ajh.27083.
     PubMed    
     
     
     
161. PATEL PC, Ball S, Jain AG, Wang C, et al
     Drivers of deep molecular response and long-term outcomes in patients with core binding factor acute myeloid leukemia.
     Am J Hematol. 2023 Sep 13. doi: 10.1002/ajh.27092.
     PubMed     Abstract available
     
     
     
162. PARDANANI A, Tefferi A, Al-Kali A, Patnaik M, et al
     Reappraisal of mast cell leukemia based on a single institution review of 16 cases: Mast cell morphology determines clinical outcome.
     Am J Hematol. 2023 Sep 9. doi: 10.1002/ajh.27089.
     PubMed     Abstract available
     
     
     
163. NATH K, Lee J, Elko TA, Levy L, et al
     Prospective analysis to determine barriers to allogeneic hematopoietic cell transplantation in patients with acute leukemia.
     Am J Hematol. 2023 Sep 9. doi: 10.1002/ajh.27084.
     PubMed     Abstract available
     
     
     
164. FANG H, Medeiros LJ, Wang W
     Acute myeloid leukemia with mutated TP53: Is this newly proposed entity oversimplifying a complex group of neoplasms?
     Am J Hematol. 2023 Sep 8. doi: 10.1002/ajh.27085.
     PubMed    
     
     
     
165. RAVANDI F, Cloos J, Buccisano F, Dillon R, et al
     Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy: Roadmap from an ELN-DAVID expert panel.
     Am J Hematol. 2023 Sep 6. doi: 10.1002/ajh.27087.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.